ADVANCES IN THE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA
Abstract
Malignant pleural mesothelioma (MPM) is a rare primary tumor originating from pleural mesothelial cells with insidious onset, high invasiveness and malignancy. Early symptoms are not obvious, lack of specific symptoms, and the diagnosis is difficult, and it depends on the pathological tissue for immunohistochemistry to confirm the diagnosis. Only a small number of patients can receive radical surgery, and the current treatment method is chemotherapy. This article reviews the diagnosis, treatment and progress of MPM diagnosis and treatment status.
References
Teta MJ, Mink PJ, Lau E, et al. US mesothelioma patterns 1973-2002: indicators of change and insights into background rates. Eur J Cancer Prev 2008; 17:525.
Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997; 145:211.
Chen Zhanqun Cancer Research and Clinic, 2018, 30(12): 871-874. DOI: 10.3760/cma.j.issn.1006-9801.2018.12.014.
Nikishov V.N. Videothoracoscopy in the diagnosis and treatment of pleural tumors // Abstract of the thesis. cand. diss. - 2002 - Kazan. – 27 p.
Pass H. Malignant pleural mesothelioma: Surgical roles and novel therapies // Clinical. Lung. Cancer. – 2001 – Vol. 3(2). – P. 102-117.
Swift S., Waller D. Surgery in alignant pleural mesothelioma / in Evidence based // Cardio-Thoracic. Surg. – 2005.
Ahamad A., Stevens C.W., Smythe W.R. et al. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest // Cancer. J. – 2003 – Vol. 9 (6). – P. 476-84.
Views:
238
Downloads:
106
Copyright (c) 2022 Zhu Jie
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.